Cancer diagnosis and treatment are being transformed by advanced genomic and molecular tools. Caris Life Sciences went public after securing FDA approval for assays integrating next-generation sequencing, AI, and comprehensive clinico-genomic data, aiming to expand precision oncology. Intelliseq partnered with Genomenon to incorporate somatic variant data into their platform enhancing interpretation of tumor genetics. Invivoscribe gained state approval for minimal residual disease assays guiding AML treatment selection. GeneCentric launched a liquid biopsy platform employing fragmentomics for superior mutation detection. These innovations collectively enhance diagnostic precision and personalize treatment across diverse oncology indications.